XOPENEX HFA
SABA MDI
Levalbuterol tartrate · Lupin Pharmaceuticals (acquired from Sunovion)
Active Medication & Mechanism
- Levalbuterol tartrate SABA45 mcg levalbuterol per actuation
R-enantiomer of racemic albuterol. Short-acting beta2-adrenergic agonist. Selectively stimulates beta2-receptors on airway smooth muscle, producing rapid bronchodilation. May have fewer beta1-mediated cardiac side effects than racemic albuterol.
FDA-Approved Dosing — Strength × Indication
Strength Regimen AsthmaExercise-Induced Bronchospasm
45 mcg
2 inhalations (90 mcg) every 4–6 hours as needed → As needed; 1 inhalation (45 mcg) may suffice in some patients
FDA Approved
Treatment or prevention of bronchospasm in adults with reversible obstructive airway disease.
Not Approved
Any age Unlike albuterol products, the Xopenex HFA label has no EIB indication and no pre-exercise dosing. The indication is limited to treatment or prevention of bronchospasm in reversible obstructive airway disease.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
45 mcg 2 inhalations (90 mcg) every 4–6 hours as needed → As needed; 1 inhalation (45 mcg) may suffice in some patients
Asthma FDA Approved
Treatment or prevention of bronchospasm in adults with reversible obstructive airway disease.
Exercise-Induced Bronchospasm Not Approved
Any age Unlike albuterol products, the Xopenex HFA label has no EIB indication and no pre-exercise dosing. The indication is limited to treatment or prevention of bronchospasm in reversible obstructive airway disease.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Rescue inhaler. Indicated for acute bronchospasm and as-needed symptom relief — onset within minutes. Increasing or frequent use signals worsening asthma control; the label advises reassessment of controller therapy.